209 related articles for article (PubMed ID: 34221872)
1. Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer.
He S; Ma J; Fang Y; Liu Y; Wu S; Dong G; Wang W; Sheng C
Acta Pharm Sin B; 2021 Jun; 11(6):1617-1628. PubMed ID: 34221872
[TBL] [Abstract][Full Text] [Related]
2. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
Han X; Wei W; Sun Y
Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
[TBL] [Abstract][Full Text] [Related]
3. MDM2-BCL-X
Chang M; Gao F; Chen J; Gnawali G; Wang W
Acta Mater Med; 2022 Jul; 1(3):333-342. PubMed ID: 36910255
[TBL] [Abstract][Full Text] [Related]
4. Repurposing AS1411 for constructing ANM-PROTACs.
Fu X; Li J; Chen X; Chen H; Wang Z; Qiu F; Xie D; Huang J; Yue S; Cao C; Liang Y; Lu A; Liang C
Cell Chem Biol; 2024 Apr; ():. PubMed ID: 38657608
[TBL] [Abstract][Full Text] [Related]
5. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
6. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
7. PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.
Qi SM; Dong J; Xu ZY; Cheng XD; Zhang WD; Qin JJ
Front Pharmacol; 2021; 12():692574. PubMed ID: 34025443
[TBL] [Abstract][Full Text] [Related]
8. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
9. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
11. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
12. Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Lai AC; Toure M; Hellerschmied D; Salami J; Jaime-Figueroa S; Ko E; Hines J; Crews CM
Angew Chem Int Ed Engl; 2016 Jan; 55(2):807-10. PubMed ID: 26593377
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives.
Fang Y; Liao G; Yu B
Acta Pharm Sin B; 2020 Jul; 10(7):1253-1278. PubMed ID: 32874827
[TBL] [Abstract][Full Text] [Related]
14. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
An S; Fu L
EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
[TBL] [Abstract][Full Text] [Related]
16. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
17. Turning chiral peptides into a racemic supraparticle to induce the self-degradation of MDM2.
Yang W; Liu W; Li X; Yan J; He W
J Adv Res; 2023 Mar; 45():59-71. PubMed ID: 35667548
[TBL] [Abstract][Full Text] [Related]
18. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
19. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
